NASDAQ:DVAX - Dynavax Technologies Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$15.95 +0.05 (+0.31 %)
(As of 06/20/2018 04:00 PM ET)
Previous Close$15.90
Today's Range$15.70 - $16.15
52-Week Range$8.15 - $24.45
Volume1.02 million shs
Average Volume1.40 million shs
Market Capitalization$993.27 million
P/E Ratio-9.22
Dividend YieldN/A
Dynavax Technologies logoDynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for oncology. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for various immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.

Receive DVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.60
Current Ratio10.85
Quick Ratio10.83


Trailing P/E Ratio-9.22
Forward P/E Ratio-7.03
P/E GrowthN/A

Sales & Book Value

Annual Sales$330,000.00
Price / Sales3,009.72
Cash FlowN/A
Price / CashN/A
Book Value$3.29 per share
Price / Book4.85


EPS (Most Recent Fiscal Year)($1.73)
Net Income$-95,150,000.00
Net Margins-31,635.17%
Return on Equity-60.61%
Return on Assets-48.71%


Outstanding Shares62,270,000

Dynavax Technologies (NASDAQ:DVAX) Frequently Asked Questions

What is Dynavax Technologies' stock symbol?

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Co. (NASDAQ:DVAX) released its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.14. The biopharmaceutical company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.82 million. Dynavax Technologies had a negative net margin of 31,635.17% and a negative return on equity of 60.61%. The firm's revenue for the quarter was up 11.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.60) EPS. View Dynavax Technologies' Earnings History.

When is Dynavax Technologies' next earnings date?

Dynavax Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Dynavax Technologies.

What price target have analysts set for DVAX?

5 analysts have issued 12-month price targets for Dynavax Technologies' stock. Their predictions range from $25.00 to $30.00. On average, they anticipate Dynavax Technologies' share price to reach $27.40 in the next twelve months. View Analyst Ratings for Dynavax Technologies.

What are Wall Street analysts saying about Dynavax Technologies stock?

Here are some recent quotes from research analysts about Dynavax Technologies stock:
  • 1. Cantor Fitzgerald analysts commented, "HEPLISAV-B Launched. Dynavax reported that HEPLISAV-B, a two-dose hepatitis B vaccine, has been launched in the U.S. with a 60-person field sales team covering 75% of the market. HEPLISAV-B was recommended by the CDC for use in the vaccination of adults, which the company believes is critical to drive broad insurance coverage and adoption. By now, 100% of Medicare lives, 74% of commercially-insured lives, and 60% of lives covered under Medicaid plans have HEPLISAV-B specific CPT codes, referencing the correct price. In the first two months following launch, the sales team met two-thirds of the targeted key accounts, corresponding to more than half of the addressable market. The sales cycle is estimated to be 6-8 weeks at this stage. As previously reported, the company has a drug supply of over 250,000 vials, with an additional 750,000 vials worth of raw material." (5/8/2018)
  • 2. According to Zacks Investment Research, "Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. " (1/10/2018)
  • 3. Cowen Inc analysts commented, "Dynavax reported a Q3 net loss of $22.1MM and ended the quarter with $192MM in." (11/3/2017)

Are investors shorting Dynavax Technologies?

Dynavax Technologies saw a increase in short interest during the month of May. As of May 31st, there was short interest totalling 8,846,142 shares, an increase of 26.9% from the May 15th total of 6,971,039 shares. Based on an average daily volume of 1,749,891 shares, the short-interest ratio is presently 5.1 days. Approximately 14.4% of the company's shares are short sold. View Dynavax Technologies' Current Options Chain.

Who are some of Dynavax Technologies' key competitors?

Who are Dynavax Technologies' key executives?

Dynavax Technologies' management team includes the folowing people:
  • Mr. Eddie Gray, CEO & Director (Age 59)
  • Dr. Dennis A. Carson, Co-Founder & Director (Age 71)
  • Mr. Michael S. Ostrach, CFO, Chief Bus. Officer & Sr. VP (Age 66)
  • Mr. David F. Novack, Sr. VP of Operations and Quality (Age 56)
  • Dr. Robert L. Coffman, Chief Scientific Officer and Sr. VP (Age 71)

Has Dynavax Technologies been receiving favorable news coverage?

Media coverage about DVAX stock has trended positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dynavax Technologies earned a daily sentiment score of 0.44 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 47.78 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are Dynavax Technologies' major shareholders?

Dynavax Technologies' stock is owned by many different of retail and institutional investors. Top institutional investors include Point72 Asset Management L.P. (8.13%), BlackRock Inc. (6.21%), Franklin Resources Inc. (4.32%), Federated Investors Inc. PA (3.89%), venBio Select Advisor LLC (2.65%) and Senvest Management LLC (2.46%). Company insiders that own Dynavax Technologies stock include David F Novack, David Louis Johnson, Michael S Ostrach, Robert Coffman and Robert Janssen. View Institutional Ownership Trends for Dynavax Technologies.

Which institutional investors are selling Dynavax Technologies stock?

DVAX stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Millennium Management LLC, Federated Investors Inc. PA, C WorldWide Group Holding A S, Allianz Asset Management GmbH, Allianz Asset Management GmbH, Senvest Management LLC and Candriam Luxembourg S.C.A.. Company insiders that have sold Dynavax Technologies company stock in the last year include David F Novack, David Louis Johnson, Michael S Ostrach and Robert Coffman. View Insider Buying and Selling for Dynavax Technologies.

Which institutional investors are buying Dynavax Technologies stock?

DVAX stock was bought by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Franklin Resources Inc., Point72 Asset Management L.P., Chicago Capital LLC, DekaBank Deutsche Girozentrale, UBS Group AG, Fisher Asset Management LLC and Rock Springs Capital Management LP. View Insider Buying and Selling for Dynavax Technologies.

How do I buy shares of Dynavax Technologies?

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dynavax Technologies' stock price today?

One share of DVAX stock can currently be purchased for approximately $15.95.

How big of a company is Dynavax Technologies?

Dynavax Technologies has a market capitalization of $993.27 million and generates $330,000.00 in revenue each year. The biopharmaceutical company earns $-95,150,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis. Dynavax Technologies employs 170 workers across the globe.

How can I contact Dynavax Technologies?

Dynavax Technologies' mailing address is 2929 SEVENTH STREET SUITE 100, BERKELEY CA, 94710. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]

MarketBeat Community Rating for Dynavax Technologies (DVAX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  280 (Vote Outperform)
Underperform Votes:  260 (Vote Underperform)
Total Votes:  540
MarketBeat's community ratings are surveys of what our community members think about Dynavax Technologies and other stocks. Vote "Outperform" if you believe DVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.